ViroStatics` Dr. Franco Lori to Present During 2009 BIO International Convention in Atlanta

SASSARI, Italy & PRINCETON, N.J.--(Business Wire)--
Dr. Franco Lori, Chief Executive Officer of ViroStatics, will present a Company
Overview during the 2009 BIO International Convention at 9:20 AM on Wednesday,
20 May, 2009 in Atlanta, Georgia, USA. Dr. Lori will discuss the Company's
recent advancements in drug discovery and development in the areas of HIV/AIDS
and cancer as well as the plans to commercialize ViroStatics` proprietary
biomarker assays.

Dr. Lori will review the company`s successes in discovering and developing a new
class of drugs known as Anti-Viral Hyper-Activation Limiting Therapeutics
(AV-HALT) that have been designed not only to suppress viral replication but
also to preserve the immune system from chronic damage. ViroStatics recently
completed a Phase II multi-national clinical trial of its lead product, VS411- a
fixed combination of drugs believed to be the first in the AV-HALT class of
drugs. The Company`s progress in developing unique biomarker assays to quantify
the functionality of the immune system`s memory T-cells against HIV as well as
other viral and bacterial pathogens will be highlighted. In addition,
ViroStatics has recently acquired an extensive library of potential AV-HALT
compounds, a number of which also may have value as anti-cancer agents. Dr. Lori
will discuss potential partnering opportunities in the areas of antivirals,
anti-cancer agents, and novel diagnostic assays.

About ViroStatics

ViroStatics srl, an Italian pharmaceutical company with operations in Sassari
and Pavia, Italy and Princeton, NJ, USA is committed to discovering and
developing novel therapeutics to address significant medical needs in HIV/AIDS,
chronic infections, cancer, and related fields. The company`s lead product,
VS411, the first fixed-dose combination of two drugs from a new class known as
Anti-Viral Hyper-Activation Limiting Therapeutics (AV-HALT) that not only
decrease HIV replication but also protect and conserve the immune system, has
recently completed a multinational Phase II clinical trial. ViroStatics has also
developed novel biomarker assays and a proprietary screening methodology to
rapidly and efficiently identify AV-HALT agents with potential to inhibit viral
replication and control the over-stimulation of the immune system that is
believed to drive the progression of HIV to AIDS. ViroStatics is committed to
expanding its pipeline and product portfolio by in-licensing early- and
late-stage compounds and exploring co-development opportunities that fit the
Company's expertise in specialty pharmaceuticals.

ViroStatics srl
Michael Stevens, PharmD, 609-951-2206
Chief Development Officer
m.stevens@virostatics.com
www.virostatics.com

Copyright Business Wire 2009